Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Saruparib |
| Synonyms | |
| Therapy Description |
Saruparib (AZD5305) inhibits PARP1, potentially leading to tumor growth inhibition (PMID: 35929986). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Saruparib | AZD 5305|AZD-5305|AZD5305 | PARP-1 Inhibitor 13 | Saruparib (AZD5305) inhibits PARP1, potentially leading to tumor growth inhibition (PMID: 35929986). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51C del | ovarian cancer | sensitive | Saruparib | Preclinical - Cell culture | Actionable | In a preclinical study, Saruparib (AZD5305) inhibited colony formation in an ovarian cancer cell line with RAD51C deletion in culture (PMID: 35929986). | 35929986 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06713369 | Phase I | Saruparib | AZD5305 hADME in Patients With Advanced Solid Malignancies (AZD5305) | Recruiting | GBR | 0 |
| NCT05938270 | Phase I | Darolutamide Darolutamide + Saruparib Saruparib | A Study to Investigate the Biological Effects of AZD5305, Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN) | Recruiting | USA | TUR | NLD | GBR | ESP | CAN | AUS | 0 |
| NCT06952803 | Phase III | Abiraterone + Prednisolone + Saruparib Abiraterone + Prednisone + Saruparib Abiraterone + Prednisone Saruparib Abiraterone + Prednisolone | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation (EvoPAR-PR02) | Recruiting | USA | TUR | SWE | POL | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
| NCT07060365 | Phase Ib/II | Saruparib | A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer | Active, not recruiting | USA | ITA | ESP | 1 |
| NCT04644068 | Phase I | Carboplatin + Paclitaxel + Saruparib Paclitaxel + Saruparib Carboplatin + Saruparib Saruparib | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA) | Active, not recruiting | USA | POL | ITA | HUN | GBR | ESP | CZE | CAN | AUS | 5 |
CKB BOOST